Frontlight ResearchEarly access
Ovarian cancer trials in South Korea
66 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleNiraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
- Where
- Seoul
- Age
- 18 years to 99 years
- People
- 390 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT05183984 · EU 2023-504166-37-00 - Phase 1Taking peopleFirst in Human Study of TORL-1-23 in Participants With Advanced Cancer
- Where
- Seoul, Suwon
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- TORL Biotherapeutics, LLC
See details and how to joinNCT05103683 - Phase 3Taking peopleInterval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
- Where
- Goyang-si, Pusan, Sejong, Seoul, Suwon
- Age
- 18 years to 80 years
- People
- 520
- Run by
- National Cancer Center, Korea
See details and how to joinNCT05827523 - Phase 2Not yet taking people in South KoreaTo Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
- Where
- Seoul
- Age
- 19 years and over
- People
- 81
- Run by
- Onconic Therapeutics Inc.
See details and how to joinNCT07370818 - Phase 2Taking peopleCATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Where
- Seoul
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- TORL Biotherapeutics, LLC
See details and how to joinNCT06690775 · EU 2024-517190-24-00 - Phase 2Taking peopleSecondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
- Where
- Goyang-si
- Age
- 19 years to 80 years
- People
- 80
- Run by
- National Cancer Center, Korea
See details and how to joinNCT07171528 - Phase 1Taking peopleA Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
- Where
- Seoul
- Age
- 19 years to 74 years
- People
- 24
- Run by
- Boryung Pharmaceutical Co., Ltd
See details and how to joinNCT07069335 - No phaseTaking peopleDiagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
- Where
- Seoul
- Age
- 19 years and over
- People
- 1,200
- Run by
- Yonsei University
See details and how to joinNCT07035587 - Phase 4Taking peopleOFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
- Where
- Seoul
- Age
- 20 years to 50 years
- People
- 418
- Run by
- Gangnam Severance Hospital
See details and how to joinNCT05333328 - Phase 2Taking peopleSecondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
- Where
- Seoul
- Age
- 18 years and over
- People
- 124
- Run by
- Korea University Guro Hospital
See details and how to joinNCT05704621 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Where
- Seoul, Suwon
- Age
- 18 years and over
- People
- 358 worldwide
- Run by
- GI Innovation, Inc.
See details and how to joinNCT05824975 - No phaseTaking peopleSalvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
- Where
- Seoul
- Age
- 19 years and over
- People
- 270
- Run by
- Yonsei University
See details and how to joinNCT05444270 - No phaseTaking peopleAssessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer
- Where
- Seoul
- Age
- 18 years and over
- People
- 108
- Run by
- Seoul National University Hospital
See details and how to joinNCT05431530 - No phaseTaking peopleDevelopment and Management of Registry in Patients With Gynecologic Cancer in Korea
- Where
- Seoul
- Age
- 18 years and over
- People
- 13,500
- Run by
- Asan Medical Center
See details and how to joinNCT05912972 - Phase 3Taking peoplePhase III Trial of Stage I Ovarian Cancer After Surgery
- Where
- Ilsandong, Namdong, Seocho, Seoul
- Age
- 20 years and over
- People
- 360 worldwide
- Run by
- Japanese Gynecologic Oncology Group
See details and how to joinNCT04063527 - No phaseTaking peopleKOrean Borderline Ovarian Tumor (KOBOT) Registry
- Where
- Changwon, Seoul
- People
- 3,000
- Run by
- Kangbuk Samsung Hospital
See details and how to joinNCT02803970